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CACNA1C hypermethylation is associated with bipolar
disorder
A Starnawska1,2,3, D Demontis1,2,3, A Pen1,4, A Hedemand1,2,3, AL Nielsen1,2,3, NH Staunstrup1,2,3, J Grove1,2,3, TD Als1,2,3, A Jarram5,
NL O’Brien5, O Mors2,6, A McQuillin5, AD Børglum1,2,3 and M Nyegaard1,2,3
The CACNA1C gene, encoding a subunit of the L-type voltage-gated calcium channel is one of the best-supported susceptibility
genes for bipolar disorder (BD). Genome-wide association studies have identiﬁed a cluster of non-coding single-nucleotide
polymorphisms (SNPs) in intron 3 to be highly associated with BD and schizophrenia. The mechanism by which these SNPs confer
risk of BD appears to be through an altered regulation of CACNA1C expression. The role of CACNA1C DNA methylation in BD has not
yet been addressed. The aim of this study was to investigate if CACNA1C DNA methylation is altered in BD. First, the methylation
status of ﬁve CpG islands (CGIs) across CACNA1C in blood from BD subjects (n= 40) and healthy controls (n= 38) was determined.
Four islands were almost completely methylated or completely unmethylated, while one island (CGI 3) in intron 3 displayed
intermediate methylation levels. In the main analysis, the methylation status of CGI 3 was analyzed in a larger sample of BD subjects
(n=582) and control individuals (n=319). Out of six CpG sites that were investigated, ﬁve sites showed signiﬁcant hypermethylation
in cases (lowest P=1.16× 10− 7 for CpG35). Nearby SNPs were found to inﬂuence the methylation level, and we identiﬁed rs2238056
in intron 3 as the strongest methylation quantitative trait locus (P=2.6 × 10− 7) for CpG35. In addition, we found an increased
methylation in females, and no difference between bipolar I and II. In conclusion, we ﬁnd that CACNA1C methylation is associated
with BD and suggest that the regulatory effect of the non-coding risk variants involves a shift in DNA methylation.
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INTRODUCTION
Bipolar disorder (BD) is a common complex mental disorder
characterized by episodes of mania, hypomania and depression.
The disorder affects ~ 1% of the population and the genetic risk
component is high with heritability estimates reaching 89%.1,2
CACNA1C is one of the most consistently associated BD genes.
CACNA1C, encodes the pore-forming α1C subunit of the L-type
voltage-gated calcium channel also referred to as Cav1.2 α1C
subunit. In the central nervous system, Cav1.2 channels are
predominantly located in the postsynaptic dendritic processes
and somata. On membrane depolarization, the Cav1.2 channels
allow postsynaptic inﬂux of calcium ions coupled with activation
of neuronal transcription factors involved in dendritic develop-
ment, neuronal survival, synaptic plasticity, as well as memory
formation and learning.3,4
The ﬁrst genome-wide association study (GWAS) that suggested
CACNA1C to be a susceptibility gene for BD was performed on
1461 BD patients and 2008 control individuals, collected as part of
the Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD) and the University College London (UCL)
sample. This GWAS showed nominally signiﬁcant association of
rs1006737 located in intron 3 of CACNA1C (P= 1× 10− 4) with BD.5
Subsequently, a larger GWAS with 4387 BD cases and 6209
controls, including overlapping samples from the ﬁrst study,
further supported the association of rs1006737, now reaching
borderline genome-wide signiﬁcance (7 × 10− 8).6 A meta analysis
of BD carried out by the Psychiatric Genomic Consortium (PGC)
Working Bipolar Group, encompassing 11 974 BD cases and
51 792 controls, identiﬁed a nearby single-nucleotide polymorph-
ism (SNP), rs4765913, as the most signiﬁcant risk SNP in CACNA1C
(P= 1.52 × 10− 8).7 The two SNPs are in moderate linkage
disequilibrium (LD) (r2 = 0.44) and both are positioned within
what is today reckoned as a narrow intronic risk locus of CACNA1C.
The most recent published GWAS of BD, performed in 9747 BD
patients and 14 278 controls, also found association of rs4765913
with BD (P= 9.96 × 10− 6).8
Shortly after the ﬁrst GWAS implicated rs1006737 in BD, several
studies found association of the same SNP with schizophrenia
(SZ).9–11 A large GWAS of SZ (including 36 989 cases and 113 075
controls) performed by the PGC identiﬁed a highly signiﬁcant
association of rs2007044 in intron 3 of CACNA1C with SZ
(P= 2.63 × 10− 17).12 A recent meta analysis further supported
association of CACNA1C with SZ, with rs4765905 positioned in
intron 3 as the best ﬁnding (P= 5.14 × 10− 17).13 It is clear, that
although arrays, imputation methods and the best-associated
SNPs may vary between studies, the association with both BP and
SZ robustly originates from a relatively narrow set of SNPs
positioned in the large intron 3 of CACNA1C.
In healthy subjects, the CACNA1C risk allele (A-allele) at
rs1006737 has been associated with increased hippocampal activity
during emotional processing and increased prefrontal activity
during executive cognition, speciﬁc patterns of brain activity that
are associated with mental illness.9 In addition, the risk allele have
also been associated with higher psychopathology scores for
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depression and anxiety,14 higher paranoid ideation scores,15
increased activity in right amygdala during fear-face
recognition,16 and increased amygdala volume,17 conﬁrming the
important role of this risk locus in the etiology of psychiatric traits.
As the risk SNPs in CACNA1C do not lead to changes in the
coding sequence of the protein, the central hypothesis guiding
the current research effort is that intron 3 contains important
regulatory functions. Results from a recent study suggest that the
intron 3 risk SNPs have a regulatory effect on three-dimensional
genome architecture associated with chromosomal loopings and
thus inﬂuence CACNA1C expression through interactions with its
transcription start site.18 DNA methylation is a powerful key
regulator of gene expression across time, tissue and lifespan,19,20
and because it is well-established that DNA methylation levels can
be inﬂuenced by nearby genetic variants, methylation changes
can provide a functional mechanism by which non-coding
sequence variation can result in phenotypic variability.21
In this study, we investigated if DNA methylation of CACNA1C is
altered in BD cases. A systematic study of all ﬁve CpG Islands
(CGIs) across the gene was ﬁrst performed to get an overview of
its methylation landscape. Subsequently, the DNA methylation of
a CGI positioned in intron 3 of CACNA1C was analyzed in a larger
case–control sample revealing signiﬁcant hypermethylation in BD
cases, which was partly driven by genotypes in the established
intronic risk locus.
MATERIALS AND METHODS
Subjects and sample preparation
BD subjects and control individuals were collected at UCL and collaborat-
ing clinical centers. The UCL cases comprised Caucasian individuals who
were ascertained and received clinical diagnoses of BD according to UK
National Health Service (NHS) psychiatrists at interview using the
categories of the International Classiﬁcation of Disease version 10
(ICD10), as described in a previous BD GWAS.5 The UCL control subjects
were recruited from London branches of the National Blood Service, from
local NHS family doctor clinics and from university student volunteers also
as described before.5 All control subjects were interviewed with the
Schizophrenia and Affective Disorders Schedule-Life Time version to
exclude all psychiatric disorders.22 The sample is partly overlapping with
the UCL sample described in Sklar et al.5 and the PGC mega-analysis of
BD.7 All subjects from the UCL sample, where DNA was still available and
where the DNA was extracted from whole blood, were used for the study,
in total 725 subjects. In addition, 176 new cases and controls were
included, collected using the same inclusion criteria, reaching a ﬁnal
sample size of 901 subjects. For a description of the overlap see
Supplementary Table 1.
For the UCL BD cases, pedigree and family history data were collected
based on self-reports by BD participants. The BD cases were categorized
according to whether there was a history of mental illness, suicide or
alcohol dependence from only the maternal or paternal side of the family.
The study was approved by the National Research Ethical Committee
and all participants provided written informed consent.
Genomic DNA was extracted from frozen whole blood using standard
procedures. For methylation analysis, 200 ng genomic DNA from each
individuals was bisulﬁte converted with the EZ DNA Methylation Kit (Zymo
Research, Irvine, CA, USA) according to manufacturer’s instructions.
EpiTYPER
EpiTYPER assays were designed for a total of 169 CpG sites spread over 5
CGIs using the EpiDesigner software (Sequenom, San Diego, CA, USA;
www.EpiDesigner.com). After PCR ampliﬁcation of bisulﬁte-converted DNA,
the amplicons were treated with Shrimp Alkaline Phosphatase (Sequenom)
followed by in vitro transcription. The resulting product was treated with
RNase A to cleave the RNA at each U nucleotide using the T-Cleavage
MassCLEAVE Kit (Sequenom). The fragments were then conditioned with
Clean Resin (Sequenom) with the protocol provided in the kit and
dispensed onto a SpectroCHIPII (Sequenom) and then analyzed on a
MassARRAY Workstation in EpiTYPER mode. Quality control and initial data
analysis were performed with the use of EpiTYPER (version 1.2, Sequenom).
Oligonucleotide sequences for the EpiTYPER assays are provided in
Supplementary Table 2.
iPLEX
iPLEX assays for six selected CpG sites in CGI 3, located in intron 3 of
CACNA1C, were designed using Assay Designer in Typer 4.0 (Sequenom)
using bioinformatically bisulﬁte-converted sequences of the targeted
region. Inosine was added to oligonucleotide sequences that contained
overlapping CpGs or SNPs. No more than one inosine was allowed in an
oligonucleotide to ensure binding speciﬁcity. The oligonucleotide
sequences for the iPLEX assays are listed in Supplementary Table 3. The
ampliﬁed products were prepared according to iPLEX manual and
dispensed on the same equipment as described above. The data were
analyzed in Allelotype mode. Quality control and detection of allele ratios
(as a measure of methylation status) were performed using Typer 4.0
(Sequenom). The data were subsequently imported into R (www.r-project.
org) for statistical analyses. During all experimental work and QC, the
investigator was blinded to affection status. Cases and controls were in
addition spread in between each other on each plate during bisulﬁte
conversion and Sequenom analysis to avoid experimental batch effects.
Statistical analyses
A non-parametric Mann–Whitney test was used to compare the levels of
DNA methylation between cases and controls, males and females, cases
with bipolar I and bipolar II, and cases with a positive versus a negative
familial history. For the analysis of familial history, cases with a maternal
history of psychiatric disorder (maternal) were compared with cases with
no mental disorder in the family (none). A similar analysis was carried out
comparing cases with paternal history versus none. Methylation quanti-
tative trait loci (mQTL) analysis was performed using the 725 subjects from
the UCL sample with Affymetrix 500 K Array genotypes available through
the NIMH Repository (https://www.nimhgenetics.org/available_data/data_
biosamples/gwas_data.php).
The mQTL analysis was performed using linear regression in PLINK23
including genotyped SNPs located in a region that encompassed the
CACNA1C gene plus 5 kb up- and downstream (focused analysis) or all
genotyped SNPs on chromosome 12 (full analysis). For the most signiﬁcant
CpG site in CGI 3, a beta regression analysis was performed to assess the
contribution of case–control status, genotype and gender on DNA
methylation level. A genetic association analysis in the UCL sample was
performed for 109 genotyped SNPs in CACNA1C and a 5 kb up- and
downstream region using a linear regression in PLINK and an
additive model.
RESULTS
Association of CACNA1C methylation with BD
The initial methylation proﬁle of the ﬁve CACNA1C CGIs in DNA
derived from the blood of BD subjects (n= 40) and controls
(n= 38) using EpiTYPER identiﬁed a large difference in DNA
methylation between the islands with relatively little overall
difference between individuals. In general, CGI 1 and CGI 5 were
found to have low methylation levels, CGI 2 and CGI 4 were highly
methylated, while CGI 3 displayed intermediate methylation
(Figure 1a).
The main methylation analysis of CGI 3 included six CpG sites
that were evaluated in BD subjects (n= 582) and control
individuals (n= 319). From this analysis, a relatively small but
highly signiﬁcant degree of hypermethylation in BD subjects was
identiﬁed for ﬁve of the six CpG sites (Figure 1b and Table 1). The
most signiﬁcant difference in methylation between BD subjects
and controls was found for CpG35 (P= 1.16 × 10− 7, Δβ= 0.03)
(Figure 1b and Table 1). The DNA methylation levels were highly
correlated between the six sites (Supplementary Table 4).
Identiﬁcation of mQTL
Because it is well-known that genetic variation can inﬂuence
methylation levels24,25 we speculated whether methylation at CGI
3 was inﬂuenced by nearby SNPs. A correlation analysis including
methylation levels at the six CpG sites and SNPs on chromosome
12 was performed for all 725 individuals for whom genotype
information was available (Supplementary Table 1). This analysis
was performed by including all genotyped SNPs within CACNA1C,
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Figure 1. DNA methylation of CACNA1C in BD cases and controls. (a) Shows the gene structure of CACNA1C and methylation landscape across
its all ﬁve CpG islands in BD cases and controls; (b) shows detailed analysis of DNA methylation levels of CpG island 3 in CACNA1C in BD cases
in comparison to controls. BD, bipolar disorder. CGI, CpG island.
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as well as 5 kb upstream and downstream of the gene (109 SNPs,
24 of whom were independent). This analysis will henceforth be
referred to as the focused analysis. In addition, an analysis
including all SNPs on chromosome 12 (15 882 SNPs, 2634
independent) was performed, referred to as the full analysis.
In the focused analysis, we found multiple SNPs that were
acting as signiﬁcant mQTL for sites in CGI 3 (Table 1). All of these
SNPs were located within the relatively narrow risk locus in intron
3. SNP rs2238056 was identiﬁed as the strongest mQTL
(P= 2.6 × 10− 7) for CpG35, the most signiﬁcantly associated CpG
site in BD subjects (Figure 2). In the full analysis, all the SNPs that
were identiﬁed as mQTL in the focused analysis were re-identiﬁed
as the best mQTL SNPs, with exception of CpG26, where
rs2239030 was replaced with rs4026015 as the most associated
mQTL SNP (Table 1). Overall the analyses demonstrate that CGI 3
methylation is inﬂuenced primarily by SNPs within the intron 3 risk
locus of CACNA1C. The mQTL for CpG35 remained signiﬁcant after
Bonferroni correction in both the focused and the full mQTL
analyses (Table 1). Interestingly, the mQTL SNPs identiﬁed in this
study were in moderate LD with the bipolar GWAS top hit
rs4765913 (index SNP) with r2 = 0.32 for rs2239030, r2 = 0.3 for
rs2238056 and r2 = 0.4 for rs10848634 according to results from
the PGC Bipolar Disorder Working Group.7 This ﬁnding supports
the hypothesis that the well-established risk SNPs in CACNA1C for
BD may have a role in DNA methylation status.
For the best CGI 3 mQTL in our study (rs2238056), the minor
C-allele was associated with increased DNA methylation levels for
all of the examined CpG sites in CGI 3 (Figure 3). A similar analysis
for rs1006737 showed that the risk minor A-allele was associated
with increased DNA methylation for all CGI 3 CpG sites in a dose-
dependent manner, which is consistent with these two minor
alleles being in LD. This effect was found in both cases and
controls (Table 1 and Supplementary Figure 1).
To test if the identiﬁed top mQTL could be risk SNPs
themselves, we carried out a genetic association analysis in the
UCL sample, including rs1006737 for comparison. Two of these
top mQTL and rs1006737 were borderline signiﬁcantly associated
with BD in the UCL sample, with better P-values in the PGC-BP
data set, most likely because of larger sample size (Supplementary
Table 5).26 Interestingly, the mQTL rs2238056 is highly associated
with SZ in the PGC SCZ 52 study (P= 1.45 × 10− 13).12 The data
suggest that the mQTL may be risk SNPs themselves, although the
high degree of LD in the region makes the identiﬁcation of the
true causal risk SNP(s) complex.
Effect of gender, bipolar I/II and familial history
We ﬁnally investigated if any of the other known variables
examined in the BD cases (Supplementary Table 1) could explain
the variation in methylation among cases and controls. We found
a hypermethylation in females compared with males. A gender-
speciﬁc analysis conﬁrmed a signiﬁcant hypermethylation in cases
both among females and males (Table 1). A beta regression
analysis of CpG35 showed signiﬁcant correlation of DNA
methylation level with affection status (P= 1.61 × 10− 5), gender
(P= 2.27 × 10− 5) and genotype of rs2238056 (P= 6.10 × 10− 5). All
these covariates inﬂuenced methylation level to approximately
the same extent. Odds of methylation increased by 15% for being
a case, 15% for being a female and by 9% for each copy of the
minor allele of rs2238056. No difference was found between cases
with or without a parental history of psychiatric disease (P40.05).
Also, no difference was found between bipolar I or bipolar II
patients (P40.05); however, due to a small number of individuals
with BD II diagnosis these results may not be generalizable. We
conclude that the CGI 3 hypermethylation in cases is driven partly,
but not entirely, by genotypes and by gender.T
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DISCUSSION
To our knowledge, this is the ﬁrst study to investigate DNA
methylation of CACNA1C in context of BD and with BD-associated
genetic risk variants. We proﬁled the DNA methylation landscape
of ﬁve CGIs in CACNA1C in blood-derived DNA and found CGI 3 to
be signiﬁcantly hypermethylated in BD subjects compared with
controls. We also found that methylation was inﬂuenced by
gender as well as by nearby genotypes.
Because of LD in the human genome, it is in general difﬁcult to
pinpoint the causal variation in a locus identiﬁed in a GWAS. For
complex traits speciﬁcally it may be impossible to demonstrate
that an implicated SNP is the causal variant. However, as pointed
out in an editorial comment in Nature Genetics,27 there should at
least be evidence that the variants identiﬁed in a GWAS show a
consistent correlation with gene expression or gene regulation
that is also highly correlated with the human trait originally
Figure 2. Overview for mQTL analysis between all SNPs genotyped in CACNA1C in the UCL sample and DNA methylation levels at the
most signiﬁcantly hypermethylated CpG site (CpG35). mQTL, methylation quantitative trait loci; SNP, single-nucleotide polymorphism;
UCL, University College London.
Figure 3. DNA methylation levels at six CpG sites in CpG island 3 of CACNA1C split by genotype of rs2238056, identiﬁed as most signiﬁcant
mQTL for the most signiﬁcantly hypermethylated CpG site (CpG35). BD, bipolar disorder; mQTL, methylation quantitative trait loci.
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assayed. In our study, we found an overall hypermethylation in
bipolar subjects, as well as increased methylation associated with
the well-established risk A-allele for susceptibility SNP rs1006737.
Our study opens up the possibility that the non-coding CACNA1C
risk SNPs may confer risk of disease through altered methylation
in intron 3.
Altered DNA methylation within a gene, as observed in this
study, has been linked to abnormal gene expression, alternative
mRNA splicing and use of alternative promoters.28–31 The exact
relationship between DNA methylation and gene expression is,
however, greatly dependent on the genomic location and tissue.29
It is therefore not straightforward to predict the effect and origin
of the increased methylation found in blood of bipolar subjects in
this study.
Previous studies investigating the correlation between CAC-
NA1C risk genotypes and gene expression have found opposite
effects of the risk allele depending on the investigated tissue. In
human cerebellum, the risk A-allele of rs1006737 was correlated
with decreased CACNA1C mRNA expression,18,32 while the same
allele was correlated with increased expression in human post-
mortem dorsolateral prefrontal cortex9 and in induced human
neurons.33 In the GTEx portal (V6 Release)34 a single signiﬁcant
eQTL for CACNA1C expression (rs7297582 in CACNA1C intron 3)
was identiﬁed in cerebellum, with the minor allele correlating with
reduced expression. As LD exist between rs7297582 and
rs1006737 (r2 = 0.71), these data are in line with the previously
published studies in cerebellum.18,32 No shared eQTLs exist
between blood and brain in GTEx with the current sample size
(338 whole blood).
Whether the CGI 3 hypermethylation observed in our study was
driven directly or indirectly by the nearby risk alleles is unknown. A
recent study investigating the mechanistic relationship between
the SNPs, DNA methylation and gene expression found that
genetic variation can act either directly (SNP affects methylation,
which change gene expression) or indirectly (SNP affects gene
expression, which affects methylation level) on DNA methylation,
and that the effect may vary with tissue.35 Studies addressing
methylation and CACNA1C expression across different brain
regions are necessary to fully uncover the molecular effect of
increased CACNA1C methylation.
Increased CACNA1C CGI 3 methylation was detected in females.
It is unclear if this gender-speciﬁc methylation effect is related to
disease because this difference was also observed in the control
subjects. Gender differences have previously been reported in
CACNA1C genetic association studies, for example, Dao et al.,36
found female-only association between mood disorders and
multiple intron 3 SNPs, that included rs1006737. Gender-speciﬁc
association was also observed by Strohmaier et al.,37 who reported
gender-speciﬁc impacts of rs1006737 in CACNA1C on a range of
personality traits, resilience factors and depressive symptoms in
3793 healthy subjects. These studies differ in the rs1006737 alleles
that were associated with mood disorders and their endopheno-
types and so the impact of gender on genetic association at this
locus remains unclear.37 It is possible that increased baseline DNA
methylation of CGI 3 in females may provide a mechanism
through which the risk allele of CACNA1C could determine sex-
speciﬁc endophenotypes of BD.
A potential limitation of this study is the use of blood samples
for methylation analysis. One argument for using blood samples
for DNA methylation in psychiatric disorders is the common
accessibility to such samples, providing adequate statistical power
to detect small effects and mQTL. Moreover, recent studies have
indicated that the DNA methylation status of many CpG sites in
the brain are mirrored in the blood,38 and that common mQTL
also exist between these two tissues, supporting the use of blood
as a surrogate tissue to delineate disease-relevant processes
within the brain.39
It is possible that medication inﬂuences DNA methylation status
of CACNA1C. Two recent studies investigated the effect of
commonly used mood stabilizers (including lithium, valproate
and carbamazepine) on human methylome in neuroblastoma cells
and whole blood of BD patients and reported signiﬁcant drug-
related changes in DNA methylation at several genes.40,41
However, both of these studies used the Inﬁnium HumanMethyla-
tion27 BeadChip array (Illumina, San Diego, CA, USA), where CGI 3
of CACNA1C is not covered, making a more comprehensive
analysis of the effects of mood stabilizers on CACNA1C methyla-
tion of high interest in the future.
Overall, we have identiﬁed CACNA1C hypermethylation in whole
blood of BD patients. Our study indicates that the regulatory effect
of risk alleles in intron 3 is accompanied by an upwards shift in
DNA methylation of the intron 3 CGI. In conclusion, CACNA1C DNA
methylation may play a role in BD.
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